Staphylococcus aureus type 336 vaccine - Nabi

Drug Profile

Staphylococcus aureus type 336 vaccine - Nabi

Alternative Names: S. aureus type 336 vaccine - Nabi

Latest Information Update: 20 Jan 2011

Price : $50

At a glance

  • Originator Nabi Biopharmaceuticals
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 20 Jan 2011 Discontinued - Phase-I/II for Staphylococcal infections in USA (Parenteral)
  • 04 Dec 2008 Phase-I/II clinical trials in Staphylococcal infections in USA (Parenteral)
  • 07 Jun 2007 Suspended - Phase-I for Staphylococcal infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top